Use of In Vivo and In Vitro Systems to Select Leishmania amazonensis Expressing Green Fluorescent Protein
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Various Leishmania species were engineered with green fluorescent protein (GFP) using episomal vectors that encoded an antibiotic resistance gene, such as aminoglycoside geneticin sulphate (G418). Most reports of GFP-Leishmania have used the flagellated extracellular promastigote, the stage of parasite detected in the midgut of the sandfly vector; fewer studies have been performed with amastigotes, the stage of parasite detected in mammals. In this study, comparisons were made regarding the efficiency for in vitro G418 selection of GFP-Leishmania amazonensis promastigotes and amastigotes and the use of in vivo G418 selection. The GFP-promastigotes retained episomal plasmid for a prolonged period and G418 treatment was necessary and efficient for in vitro selection. In contrast, GFP-amastigotes showed low retention of the episomal plasmid in the absence of G418 selection and low sensitivity to antibiotics in vitro. The use of protocols for G418 selection using infected BALB/c mice also indicated low sensitivity to antibiotics against amastigotes in cutaneous lesions.
Abstract
Various Leishmania species were engineered with green fluorescent protein (GFP) using episomal vectors that encoded an antibiotic resistance gene, such as aminoglycoside geneticin sulphate (G418). Most reports of GFP-Leishmania have used the flagellated extracellular promastigote, the stage of parasite detected in the midgut of the sandfly vector; fewer studies have been performed with amastigotes, the stage of parasite detected in mammals. In this study, comparisons were made regarding the efficiency for in vitro G418 selection of GFP-Leishmania amazonensis promastigotes and amastigotes and the use of in vivo G418 selection. The GFP-promastigotes retained episomal plasmid for a prolonged period and G418 treatment was necessary and efficient for in vitro selection. In contrast, GFP-amastigotes showed low retention of the episomal plasmid in the absence of G418 selection and low sensitivity to antibiotics in vitro. The use of protocols for G418 selection using infected BALB/c mice also indicated low sensitivity to antibiotics against amastigotes in cutaneous lesions.
참고문헌 (23)
- Ha DS, "Use of the green fluorescent protein as a marker in transfected Leishmania", Mol Biochem Parasitol, 77, pp.57~64 (1996)
- Misslitz A, "Targeted integration into a rRNA locus results in uniform and high level expression of transgenes in Leishmania amastigotes", Mol Biochem Parasitol, 107, pp.251~261 (2000)
- Sereno D, "DNA transformation of Leishmania infantum axenic amastigotes and their use in drug screening", Antimicrob Agents Chemother, 45, pp.1168~1173 (2001)
- Kamau SW, "Expression of green fluorescent protein as a marker for effects of antileishmanial compounds in vitro", Antimicrob Agents Chemother, 45, pp.3654~3656 (2001)
- Chan MM, "A microplate assay for Leishmania amazonensis promastigotes expressing multimeric green fluorescent protein", Parasitol Res, 89, pp.266~271 (2003)
- Okuno T, "Applications of recombinant Leishmania amazonensis expressing egfp or the beta-galactosidase gene for drug screening and histopathological analysis", Exp Anim, 52, pp.109~118 (2003)
- Singh N, "Transgenic Leishmania donovani clinical isolates expressing green fluorescent protein constitutively for rapid and reliable ex vivo drug screening", J Antimicrob Chemother, 64, pp.370~374 (2009)
- Varela M RE, "Leishmania (Viannia) panamensis: An in vitro assay using the expression of GFP for screening of antileishmanial drug", Exp Parasitol, 122, pp.134~139 (2009)
- Singh N, "Short report: fluorescent Leishmania: application to anti-leishmanial drug testing", Am J Trop Med Hyg, 71, pp.400~402 (2004)
- Kain SR, "Green fluorescent protein (GFP): Applications in cell-based assays for drug discovery", Drug Discov Today, 4, pp.304~312 (1999)
- Mehta SR, "Real-time in vivo green fluorescent protein imaging of a murine leishmaniasis model as a new tool for Leishmania vaccine and drug discovery", Clin Vaccine Immunol, 15, pp.1764~1770 (2008)
- Roy G, "Episomal and stable expression of the luciferase reporter gene for quantifying Leishmania spp. infections in macrophages and in animal models", Mol Biochem Parasitol, 110, pp.195~206 (2000)
- Shimony O, "Rapid fluorescent assay for screening drugs on Leishmania amastigotes", J Microbiol Methods, 75, pp.196~200 (2008)
- Grimaldi G Jr, "Leishmaniases of the new world: Current concepts and implications for future research", Clin Microbiol Rev, 6, pp.230~250 (1993)
- Desjeux P, "Leishmaniasis: Current situation and new perspectives", Comp Immunol Microbiol Infect Dis, 27, pp.305~318 (2004)
- Rossi-Bergmann B, "Use of fluorescent Leishmania for faster quantitation of parasite growth in vitro and in vivo", Mem Inst Oswaldo Cruz, 94, pp.74~ (1999)
- Arrais-Silva WW, "Hyperbaric oxygen therapy reduces the size of Leishmania amazonensis-induced soft tissue lesions in mice", Acta Trop, 98, pp.130~136 (2006)
- Boeck P, "Synthesis of chalcone analogues with increased antileishmanial activity", Bioorg Med Chem, 14, pp.1538~1545 (2006)
- Colhone MC, "Effect of hypoxia on macrophage infection by Leishmania amazonensis", J Parasitol, 90, pp.510~515 (2004)
- Naumov GN, "Cellular expression of green fluorescent protein, coupled with high-resolution in vivo videomicroscopy, to monitor steps in tumor metastasis", J Cell Sci, 112, pp.1835~1842 (1999)
- Wade-Martins R, "Long-term stability of large insert genomic DNA episomal shuttle vectors in human cells", Nucleic Acids Res, 27, pp.1674~1682 (1999)
- Murphy NB, "Use of an in vivo system to determine the G418 resistance phenotype of bloodstream-form Trypanosoma brucei brucei transfectants", Antimicrob Agents Chemother, 37, pp.1167~1170 (1993)
- Appel KF, "A multicopy vector system for genetic studies in Mucor circinelloides and other zygomycetes", Mol Genet Genomics, 271, pp.595~602 (2004)